These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 38057209)

  • 1. Modeling the optimal seasonal monoclonal antibody administration strategy for respiratory syncytial virus (RSV) prevention based on age-season specific hospitalization rate of RSV in Suzhou, China, 2016-2022.
    Ren S; Chen Q; Zhang Y; Yi L; Qian C; Lu Y; Shen J; Liu X; Jiang M; Wang B; Song J; Shao X; Zhang T; Tian J; Zhao G
    Vaccine; 2024 Jan; 42(2):352-361. PubMed ID: 38057209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
    Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
    Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalization rate of respiratory syncytial virus-associated acute lower respiratory infection among young children in Suzhou, China, 2010-2014.
    Ren S; Shi T; Shan W; Shen S; Chen Q; Zhang W; Dai Z; Xue J; Zhang T; Tian J; Zhao G
    Influenza Other Respir Viruses; 2022 Jul; 16(4):789-799. PubMed ID: 34989118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
    Li X; Bilcke J; Vázquez Fernández L; Bont L; Willem L; Wisløff T; Jit M; Beutels P;
    J Infect Dis; 2022 Aug; 226(Suppl 1):S95-S101. PubMed ID: 35292816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
    Moline HL; Tannis A; Toepfer AP; Williams JV; Boom JA; Englund JA; Halasa NB; Staat MA; Weinberg GA; Selvarangan R; Michaels MG; Sahni LC; Klein EJ; Stewart LS; Schlaudecker EP; Szilagyi PG; Schuster JE; Goldstein L; Musa S; Piedra PA; Zerr DM; Betters KA; Rohlfs C; Albertin C; Banerjee D; McKeever ER; Kalman C; Clopper BR; ; McMorrow ML; Dawood FS
    MMWR Morb Mortal Wkly Rep; 2024 Mar; 73(9):209-214. PubMed ID: 38457312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of birth month in the burden of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in Croatia.
    Li Y; Batinović E; Milić P; Markić J
    PLoS One; 2022; 17(9):e0273962. PubMed ID: 36054117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
    Ares-Gómez S; Mallah N; Santiago-Pérez MI; Pardo-Seco J; Pérez-Martínez O; Otero-Barrós MT; Suárez-Gaiche N; Kramer R; Jin J; Platero-Alonso L; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Piñeiro-Sotelo M; Malvar-Pintos A; González-Pérez JM; Rodríguez-Tenreiro-Sánchez C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F;
    Lancet Infect Dis; 2024 Aug; 24(8):817-828. PubMed ID: 38701823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burden and severity of children's hospitalizations by respiratory syncytial virus in Portugal, 2015-2018.
    Bandeira T; Carmo M; Lopes H; Gomes C; Martins M; Guzman C; Bangert M; Rodrigues F; Januário G; Tomé T; Azevedo I
    Influenza Other Respir Viruses; 2023 Jan; 17(1):e13066. PubMed ID: 36377322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015-2018.
    Martinón-Torres F; Carmo M; Platero L; Drago G; López-Belmonte JL; Bangert M; Díez-Domingo J
    BMC Infect Dis; 2023 Jun; 23(1):385. PubMed ID: 37291530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus-associated hospitalizations among children: an Italian retrospective observational study.
    Fortunato F; Campanozzi A; Maffei G; Arena F; Carri VD; Rollo T; Lopalco PL; Martinelli D
    Ital J Pediatr; 2024 Mar; 50(1):45. PubMed ID: 38454523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales.
    Hodgson D; Koltai M; Krauer F; Flasche S; Jit M; Atkins KE
    Vaccine; 2022 Nov; 40(49):7151-7157. PubMed ID: 36328884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries.
    Getaneh AM; Li X; Mao Z; Johannesen CK; Barbieri E; van Summeren J; Wang X; Tong S; Baraldi E; Phijffer E; Rizzo C; van Wijhe M; Heikkinen T; Bont L; Willem L; Jit M; Beutels P; Bilcke J;
    Vaccine; 2023 Feb; 41(9):1623-1631. PubMed ID: 36737318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study.
    Brault A; Pontais I; Enouf V; Debeuret C; Bloch E; Paireau J; Rameix-Welti MA; White M; Baudemont G; Lina B; Parent du Châtelet I; Casalegno JS; Vaux S; Cauchemez S
    Lancet Child Adolesc Health; 2024 Oct; 8(10):721-729. PubMed ID: 39208833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities.
    Liu D; Leung K; Jit M; Wu JT
    Vaccine; 2021 Sep; 39(39):5490-5498. PubMed ID: 34454783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
    Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
    N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study.
    Martinón-Torres F; Carmo M; Platero L; Drago G; López-Belmonte JL; Bangert M; Díez-Domingo J; Garcés-Sánchez M
    BMC Infect Dis; 2022 Sep; 22(1):759. PubMed ID: 36175846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina.
    Guiñazú G; Dvorkin J; Mahmud S; Baral R; Pecenka C; Libster R; Clark A; Caballero MT
    Vaccine; 2024 Oct; 42(23):126234. PubMed ID: 39154512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus.
    Debessai H; Jones JM; Meaney-Delman D; Rasmussen SA
    Obstet Gynecol; 2024 Mar; 143(3):e54-e62. PubMed ID: 38061043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospitalizations for acute lower respiratory tract infection due to respiratory syncytial virus in Thailand, 2008-2011.
    Naorat S; Chittaganpitch M; Thamthitiwat S; Henchaichon S; Sawatwong P; Srisaengchai P; Lu Y; Chuananon S; Amornintapichet T; Chantra S; Erdman DD; Maloney SA; Akarasewi P; Baggett HC
    J Infect Dis; 2013 Dec; 208 Suppl 3():S238-45. PubMed ID: 24265483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States.
    Ektare V; Lang J; Choi Y; Finelli L
    Vaccine; 2022 Oct; 40(42):6064-6073. PubMed ID: 36096968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.